962 related articles for article (PubMed ID: 31156534)
21. Associations between quantitative [
Timmers T; Ossenkoppele R; Wolters EE; Verfaillie SCJ; Visser D; Golla SSV; Barkhof F; Scheltens P; Boellaard R; van der Flier WM; van Berckel BNM
Alzheimers Res Ther; 2019 Jul; 11(1):60. PubMed ID: 31272512
[TBL] [Abstract][Full Text] [Related]
22. The Evaluation of Tau Deposition with [
Jantarato A; Vachatimanont S; Boonkawin N; Yaset S; Kunawudhi A; Promteangtrong C; Assanasen J; Mahanonda N; Chotipanich C
Mol Imaging; 2021; 2021():6640054. PubMed ID: 34381315
[TBL] [Abstract][Full Text] [Related]
23. Regional amyloid deposition in amnestic mild cognitive impairment and Alzheimer's disease evaluated by [18F]AV-45 positron emission tomography in Chinese population.
Huang KL; Lin KJ; Hsiao IT; Kuo HC; Hsu WC; Chuang WL; Kung MP; Wey SP; Hsieh CJ; Wai YY; Yen TC; Huang CC
PLoS One; 2013; 8(3):e58974. PubMed ID: 23516589
[TBL] [Abstract][Full Text] [Related]
24. 18F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer's Disease.
Okafor M; Nye JA; Shokouhi M; Shaw LM; Goldstein F; Hajjar I
J Alzheimers Dis; 2020; 74(2):589-601. PubMed ID: 32065800
[TBL] [Abstract][Full Text] [Related]
25. Associations Between Amyloid and Tau Pathology, and Connectome Alterations, in Alzheimer's Disease and Mild Cognitive Impairment.
King-Robson J; Wilson H; Politis M;
J Alzheimers Dis; 2021; 82(2):541-560. PubMed ID: 34057079
[TBL] [Abstract][Full Text] [Related]
26. The structural MRI markers and cognitive decline in prodromal Alzheimer's disease: a 2-year longitudinal study.
Wei H; Kong M; Zhang C; Guan L; Ba M;
Quant Imaging Med Surg; 2018 Nov; 8(10):1004-1019. PubMed ID: 30598878
[TBL] [Abstract][Full Text] [Related]
27. Parametric Estimation of Reference Signal Intensity for Semi-Quantification of Tau Deposition: A Flortaucipir and [
Zhang H; Wang M; Lu J; Bao W; Li L; Jiang J; Zuo C;
Front Neurosci; 2021; 15():598234. PubMed ID: 34234637
[TBL] [Abstract][Full Text] [Related]
28. Parametric estimation of reference signal intensity in the quantification of amyloid-beta deposition: an
Wang M; Yan Z; Zhang H; Lu J; Li L; Yu J; Wang J; Matsuda H; Zuo C; Jiang J;
Quant Imaging Med Surg; 2021 Jan; 11(1):249-263. PubMed ID: 33392026
[TBL] [Abstract][Full Text] [Related]
29. Tau
Whittington A; Gunn RN;
J Nucl Med; 2021 Sep; 62(9):1292-1300. PubMed ID: 33517326
[TBL] [Abstract][Full Text] [Related]
30. Data-driven approaches for tau-PET imaging biomarkers in Alzheimer's disease.
Vogel JW; Mattsson N; Iturria-Medina Y; Strandberg OT; Schöll M; Dansereau C; Villeneuve S; van der Flier WM; Scheltens P; Bellec P; Evans AC; Hansson O; Ossenkoppele R; ;
Hum Brain Mapp; 2019 Feb; 40(2):638-651. PubMed ID: 30368979
[TBL] [Abstract][Full Text] [Related]
31. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
32. Head-to-head comparison between plasma p-tau217 and flortaucipir-PET in amyloid-positive patients with cognitive impairment.
Mundada NS; Rojas JC; Vandevrede L; Thijssen EH; Iaccarino L; Okoye OC; Shankar R; Soleimani-Meigooni DN; Lago AL; Miller BL; Teunissen CE; Heuer H; Rosen HJ; Dage JL; Jagust WJ; Rabinovici GD; Boxer AL; La Joie R
Alzheimers Res Ther; 2023 Sep; 15(1):157. PubMed ID: 37740209
[TBL] [Abstract][Full Text] [Related]
33.
Chang Y; Li C; Yang H; Wu Y; Xu B; Zhang J; Wang R
Front Neurosci; 2020; 14():745. PubMed ID: 32848542
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders.
Leuzy A; Smith R; Ossenkoppele R; Santillo A; Borroni E; Klein G; Ohlsson T; Jögi J; Palmqvist S; Mattsson-Carlgren N; Strandberg O; Stomrud E; Hansson O
JAMA Neurol; 2020 Aug; 77(8):955-965. PubMed ID: 32391858
[TBL] [Abstract][Full Text] [Related]
35. Improved Correlation of
Ikari Y; Akamatsu G; Matsumoto K; Yamane T; Senda M; Fukuchi K;
J Nucl Med Technol; 2024 Apr; ():. PubMed ID: 38627012
[TBL] [Abstract][Full Text] [Related]
36. Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: (18)F-florbetapir (AV-45/Amyvid) PET study.
Wu KY; Liu CY; Chen CS; Chen CH; Hsiao IT; Hsieh CJ; Lee CP; Yen TC; Lin KJ
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1067-76. PubMed ID: 26739329
[TBL] [Abstract][Full Text] [Related]
37. Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition.
Vemuri P; Lowe VJ; Knopman DS; Senjem ML; Kemp BJ; Schwarz CG; Przybelski SA; Machulda MM; Petersen RC; Jack CR
Alzheimers Dement (Amst); 2017; 6():21-30. PubMed ID: 28138510
[TBL] [Abstract][Full Text] [Related]
38. Multiparametric imaging hippocampal neurodegeneration and functional connectivity with simultaneous PET/MRI in Alzheimer's disease.
Yan S; Zheng C; Cui B; Qi Z; Zhao Z; An Y; Qiao L; Han Y; Zhou Y; Lu J
Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2440-2452. PubMed ID: 32157432
[TBL] [Abstract][Full Text] [Related]
39. Relationships Between Cognition and Neuropathological Tau in Alzheimer's Disease Assessed by 18F Flortaucipir PET.
Devous MD; Fleisher AS; Pontecorvo MJ; Lu M; Siderowf A; Navitsky M; Kennedy I; Southekal S; Harris TS; Mintun MA
J Alzheimers Dis; 2021; 80(3):1091-1104. PubMed ID: 33682705
[TBL] [Abstract][Full Text] [Related]
40. Brain network alterations in individuals with and without mild cognitive impairment: parallel independent component analysis of AV1451 and AV45 positron emission tomography.
Li Y; Yao Z; Yu Y; Zou Y; Fu Y; Hu B;
BMC Psychiatry; 2019 Jun; 19(1):165. PubMed ID: 31159754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
